Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
Related Research units
Abstract
Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400 mg/d can be unsatisfactory. Optimization of treatment is warranted.
Bibliographical data
| Original language | English |
|---|---|
| Article number | 12 |
| ISSN | 0732-183X |
| Publication status | Published - 2011 |
| pubmed | 21422420 |
|---|
